There was a higher proportion of patients with an Hb level of ≥110 g/L in the > 1000 mg dose group, irrespective of ESA treatment – this is an important observation as the UK NICE guidance recommends the investigation and management of anaemia in patients with an Hb level of <110 g/L [7]. This evidence concerns the gene GSTM1 and anemia (phenotype).